News

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...
A federal panel of medical experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. The 15-member ...
In a statement today, GlaxoSmithKline Malaysia (GSK) highlighted that RSV is a common and highly contagious virus that can lead to serious health complications, including lower respiratory tract ...
A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to ...
On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...